Aims and Objectives: To determine the safety and efficacy of low dose, single loading dose and standard Pritchard regimen of magnesium sulphate in treatment of Antepartum Eclampsia. To compare maternal and perinatal outcome in above three regimen groups. Methodology: The present study is a prospective study conducted in the department of Obstetrics and Gynaecology at Government General Hospital, Ananthapuramu, during the period of July, 2014 – June, 2015 after obtaining clearance from Hospital Ethical Committee. Results: The three groups were compared in terms of safety and efficacy of treatment, serum magnesium level, magnesium delivery interval, maternal and perinatal outcome. Low dose regimen groups have prevented seizures effectively in 93.4% cases. MgSO4 toxicity was found less in the low dose groups. In group A 83.3% cases, in group B 80% cases and in Group C 76.7% cases were delivered vaginally and caesarean section was done for fetal and obstetric indications in 16.7% cases in Group A, 20% in group B and 23.3% in Group C which did not differ much in the three groups. There was no maternal morbidity or mortality in this study. The Perinatal mortality was 50% in group A, 35.4% in group B and 29% in group C. Conclusion: The present study provides further strong support for the routine use of magnesium sulphate for Eclampsia. As long as there is adequate urinary output, clinical monitoring appears to be sufficient with no difference in maternal outcome.